The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kleo Pharmaceuticals‘ KP1237, an investigational treatment for multiple myeloma. The designation grants various development incentives to medications that address rare disorders affecting fewer than 200,000 people annually in the U.S. Incentives include regulatory support and financial benefits that will help accelerate the clinical development of KP1237, and seven years of marketing exclusivity if regulatory approval is ultimately granted. “We are pleased to…
You must be logged in to read/download the full post.
The post Investigational Myeloma Treatment KP1237 Wins FDA Orphan Drug Status appeared first on BioNewsFeeds.